Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.

Article Details

Citation
Copy to clipboard

Hu X, Bian C, Zhao X, Yi T

Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.

Front Immunol. 2022 Oct 6;13:1034903. doi: 10.3389/fimmu.2022.1034903. eCollection 2022.

PubMed ID
36275669 [ View in PubMed
]
Abstract

Ovarian cancer, one of the most common gynecological malignancies, is characterized by high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the mainstay of ovarian cancer treatment, and most women experience recurrence after standard care therapies. There is compelling evidence that ovarian cancer is an immunogenic tumor. For example, the accumulation of tumor-infiltrating lymphocytes is associated with increased survival, while increases in immunosuppressive regulatory T cells are correlated with poor clinical outcomes. Therefore, immunotherapies targeting components of the tumor microenvironment have been gradually integrated into the existing treatment options, including immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immunotherapies have changed guidelines for maintenance treatment and established a new paradigm in ovarian cancer treatment. Despite single immunotherapies targeting DNA repair mechanisms, immune checkpoints, and angiogenesis bringing inspiring efficacy, only a subset of patients can benefit much from it. Thus, the multi-immunotherapy investigation remains an active area for ovarian cancer treatment. The current review provides an overview of various clinically oriented forms of multi-immunotherapy and explores potentially effective combinational therapies for ovarian cancer.

DrugBank Data that Cites this Article

Drugs